XOMA
XOMA
US98419J2069
XOMA Royalty Corporation
Loading chart...

Company Profile

-

Latest News

Ligand Pharmaceuticals (LGND): Massive XOMA Acquisition Doubles The Royalty Book
LGND
Ligand Pharmaceuticals Highlights XOMA-Fueled Royalty Growth, $700M in Deployable Capital
LGNDPVLA
LGND: XOMA Acquisition Closed
Zacks Small Cap Research • 08/10/2026

LGND: XOMA Acquisition Closed

LGND
LGNDXOMA
XOMA Royalty Announces Closing of Its Acquisition by Ligand
XOMALGND
Ligand Completes Acquisition of XOMA Royalty, Creating a Portfolio of More than 200 Biopharmaceutical Royalty Assets
LGND

Related stocks

ZVRA
ZVRA • United States
Zevra Therapeutics, Inc.
11.39 USD
676.38M USD 1Y +3.4%
ABUS
ABUS • United States
Arbutus Biopharma Corporation
4.22 USD
646.82M USD 1Y +0%
ACRS
ACRS • United States
Aclaris Therapeutics, Inc.
3.83 USD
563.77M USD 1Y +99.5%
AVTX
AVTX • United States
Avalo Therapeutics, Inc.
13.65 USD
732.05M USD 1Y -5.6%
CTNM
CTNM • United States
Contineum Therapeutics, Inc.
13.38 USD
503.37M USD 1Y +8.4%
LXRX
LXRX • United States
Lexicon Pharmaceuticals, Inc.
1.68 USD
747.53M USD 1Y +23.1%
ARDX
ARDX • United States
Ardelyx, Inc.
3.28 USD
846.86M USD 1Y -35.4%
GERN
GERN • United States
Geron Corporation
1.23 USD
787.03M USD 1Y -11.6%

Key Metrics & Overview

Detailed metrics & financial data of the company

Company Profile
4 Metrics
Country
United States
Region
North America
Sector
Healthcare
Industry
Biotechnology

🛡️ Risk & Structural Analysis

Multi-Factor Risk Model & Market Data

6/7 High
3Y Volatility
-
Max Drawdown (3Y)
-
Sharpe Ratio (3Y)
-
Beta Factor
0.86
Size Class
Small Cap
Notes & Warnings
Single Stock Risk: Investing in an individual stock carries full company and insolvency risk (no fund diversification).
🔴 Low analyst coverage – higher uncertainty in growth estimates & projections
ende